True Wealth Design’s Fennec Pharmaceuticals FENC Stock Holding History

True Wealth Design’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$97	Sell	9 -9	-50%	-$73	﹤0.01%	2542
2026 Q1	$111	Buy	18 +17	+1,700%	+$131	﹤0.01%	2451
2025 Q4	$8	Buy	+1	New	+$8	﹤0.01%	2533

Other funds holding FENC

Eleva Capital Paris, France $343M AUM

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

True Wealth Design's FENC Position: Q2 2026 in Review

True Wealth Design reduced its Fennec Pharmaceuticals (FENC) stake by 50% in Q2 2026, selling an estimated $73 and leaving 9 shares worth $97. The position accounts for ﹤0.01% of the portfolio, ranked #2542.

True Wealth Design first reported a position in FENC in Q4 2025 and has held it in 3 quarters since. The position peaked at $111 in Q1 2026. 5 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

True Wealth Design held 9 shares of Fennec Pharmaceuticals worth $97 as of Q2 2026.
True Wealth Design sold 9 Fennec Pharmaceuticals shares in Q2 2026, an estimated $73.
Fennec Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2542 holding.
True Wealth Design first reported a position in Fennec Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
True Wealth Design's Fennec Pharmaceuticals position peaked at $111 in Q1 2026.
5 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.